SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of December 2022
Commission File Number 001-40316
VECTIVBIO HOLDING AG
(Exact name of registrant as specified in its charter)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Announcement of Results of the Companys Extraordinary General Meeting of Shareholders
On December 9, 2022, VectivBio Holding AG, or the Company, issued a press release announcing the results of the Companys Extraordinary General Meeting of Shareholders, which was held at 10:00 a.m. (Swiss time) on December 9, 2022, at the Companys offices at Aeschenvorstadt 36, 4051 Basel, Switzerland. A copy of the press release is filed as Exhibit 99.1 hereto.
Incorporation by Reference
The Company hereby incorporates by reference the information contained in the body of this Report on Form 6-K and in Exhibit 99.1 into the Companys registration statements on Form S-8 (File No. 333-255524) and Form F-3 (File Nos. 333-264653 and 333-265546) (including any prospectuses forming a part of such registration statements) and deems them to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
|99.1||Press Release, dated December 9, 2022.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|VECTIVBIO HOLDING AG|
|December 9, 2022||By:|
|Chief Executive Officer|
VectivBio Announces Results of Extraordinary General Meeting
December 9, 2022
Wouter Joustra Elected to the Board of Directors
BASEL, Switzerland, Dec. 9, 2022 (GLOBE NEWSWIRE) VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022.
Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion´s Growth Opportunities Funds, which concentrates on investing in late stage life sciences companies. Previously, Mr. Joustra was a Senior Trader, as well as Executive Board member of the life sciences franchise at Kempen, a European boutique investment bank. In this role, Mr. Joustra managed Kempens trading portfolio, and he was involved in deal structuring and equity capital markets transactions, as well as larger block trades. Until Gyroscope Therapeuticss acquisition by Novartis for up to $1.5 billion, Mr. Joustra served as a member of Gyroscope Therapeuticss board of directors. Mr. Joustra is currently on the board of Forbions SPAC vehicle, Forbion European Acquisition Corp. (NASDAQ: FRBN), in addition to being a board observer at NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Mr. Joustra holds an M.Sc. in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.
We are pleased to add Wouter to the VectivBio Board of Directors. His deep experience in life-science capital markets will benefit VectivBio as we enter our next stage of growth, said Tom Woiwode, VectivBio Board Chairman.
VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Lead product candidate apraglutide is a next-generation, long-acting synthetic GLP-2 analog being developed for a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology, including short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD).
VectivBio is also advancing its modular, small molecule CoMET platform to address a broad range of previously undruggable Inherited Metabolic Diseases (IMDs). CoMET leverages innovative chemistry, based on a proprietary stabilized pantetheine backbone, to restore fundamental cellular metabolism in pediatric populations with IMDs characterized by a deficit of energy metabolism caused by the depletion of functional Coenzyme A (CoA). Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA), propionic acidemia (PA), and other organic acidemias.
Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.
SVP, Investor Relations and Strategic Communications